Theranos Investor Conference Presentation Deck

Immunochemistry: Method Comparison Study Overview Population Samples type and matrix Comparator Number of miniLabs Study design Analysis At risk for Herpes (intended use population) Venous serum Focus HerpeSelect 1 & 2 Immunoblot 7 CLSI EP12-A2 Compute negative and positive percent agreement compared to comparative method This technology has not been cleared or approved by the FDA and is not for sale in the United States. theranos 35

View entire presentation